Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients

[1] Kopetz S(2009)Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 3677-83

[2] Chang GJ(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-42

[3] Overman MJ(2013)Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Oncologist 18 1004-12

[4] Eng C(2010)Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review Ann Oncol 21 1152-62

[5] Sargent DJ(2015)Should FOLFOXIRI plus bevacizumab be the standard first-line therapy in metastatic colorectal cancer? Oncologist 20 236-8

[6] Larson DW(2010)Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador Curr Oncol 17 12-16

[7] Grothey A(2011)Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis Clin Colorectal Cancer 10 97-101

[8] Vauthey JN(2007)Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 1788-95

[9] Nagorney DM(2011)Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes Ann Oncol 22 1404-12

[10] McWilliams RR(2006)Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 1112-8

[1] Kopetz S(2009)Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 3677-83

[2] Chang GJ(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-42

[3] Overman MJ(2013)Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Oncologist 18 1004-12

[4] Eng C(2010)Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review Ann Oncol 21 1152-62

[5] Sargent DJ(2015)Should FOLFOXIRI plus bevacizumab be the standard first-line therapy in metastatic colorectal cancer? Oncologist 20 236-8

[6] Larson DW(2010)Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador Curr Oncol 17 12-16

[7] Grothey A(2011)Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis Clin Colorectal Cancer 10 97-101

[8] Vauthey JN(2007)Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 1788-95

[9] Nagorney DM(2011)Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes Ann Oncol 22 1404-12

[10] McWilliams RR(2006)Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 1112-8